Abionyx Pharma SA (ABNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million ≈ $-1.99 Million USD) by net assets (€5.41 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABNX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Abionyx Pharma SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LI Ming Development Construction Co Ltd
TWO:6212
|
-0.035x |
|
Zhulian Corporation Bhd
KLSE:5131
|
-0.017x |
|
Vascon Engineers Limited
NSE:VASCONEQ
|
-0.063x |
|
United Bancorp Inc
NASDAQ:UBCP
|
0.005x |
|
Negri Sembilan Oil Palms Bhd
KLSE:2038
|
0.080x |
|
Vittia Fertilizantes
SA:VITT3
|
0.172x |
|
Quantum Graphite Ltd
AU:QGL
|
-0.115x |
|
Charlton Aria Acquisition Corporation Class A Ordinary Shares
NASDAQ:CHAR
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Abionyx Pharma SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.485x | -3.88% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
€-3.70 Million ≈ $-4.32 Million |
-0.467x | +0.37% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
€-3.36 Million ≈ $-3.93 Million |
-0.469x | +25.24% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
€-6.69 Million ≈ $-7.82 Million |
-0.627x | -593.63% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
€-599.00K ≈ $-700.29K |
-0.090x | +84.75% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
€-3.95 Million ≈ $-4.62 Million |
-0.593x | +62.11% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
€-6.00 Million ≈ $-7.02 Million |
-1.564x | -52.89% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
€-9.09 Million ≈ $-10.63 Million |
-1.023x | +22.15% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
€-19.20 Million ≈ $-22.44 Million |
-1.314x | -218.16% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
€-13.71 Million ≈ $-16.03 Million |
-0.413x | +99.85% |
| 2014-12-31 | €12.00K ≈ $14.03K |
€-3.30 Million ≈ $-3.86 Million |
-275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
€-14.49 Million ≈ $-16.94 Million |
-2.352x | -- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more